Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3024514 | 1.00 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29401282 | 1.00 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30865523 | 0.98 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL2617390 | 0.98 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL30722280 | 0.98 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1172846 | 0.98 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1172849 | 0.98 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7644080 | 0.96 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| Potassium SCHEMBL7644087 | 0.96 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| Ether SCHEMBL27515108 | 0.92 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115090422-B | Amino acid type collector, and preparation method and application thereof | 山东理工大学 | 2024-04-26 | — | — | CN | claimed |
| CN-115090422-A | Amino acid type collecting agent and preparation method and application thereof | 山东理工大学 | 2022-09-23 | — | — | CN | claimed |
| US-20240199948-A1 | POLYMER | SUMITOMO CHEMICAL CO., LTD. (JP) | 2024-06-20 | — | — | US | disclosed |
| CN-115090422-B | Amino acid type collector, and preparation method and application thereof | 山东理工大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-113999136-B | Rhein derivative, preparation method and application thereof, and liver cancer inhibitor specifically expressed by RECQL4 | 山东第一医科大学(山东省医学科学院) | 2023-08-04 | — | — | CN | disclosed |
| US-20230174497-A1 | RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-115090422-A | Amino acid type collecting agent and preparation method and application thereof | 山东理工大学 | 2022-09-23 | — | — | CN | disclosed |
| CN-113999136-A | Rheum officinale amide derivative, preparation method and application thereof, and liver cancer inhibitor specifically expressed by RECQL4 | 山东第一医科大学(山东省医学科学院) | 2022-02-01 | — | — | CN | disclosed |
| US-20160168312-A1 | ALLOPHANATE COMPOSITION | VENCOREX FRANCE (FR) | 2016-06-16 | — | — | US | disclosed |
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-1860113-A1 | Ectonucleotidase inhibitors | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2007-11-28 | — | — | EP | disclosed |
| CN-1683365-A | Substituted dioxopentacyclic derivative and its use in preparing neuro regulator | POISON MEDICINE INST ACADEMY O (CN) | 2005-10-19 | — | — | CN | disclosed |
| US-20050038109-A1 | Macromolecular platinum chelates | ACCESS PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005002508-A2 | MACROMOLECULAR PLATINUM CHELATES | ACCESS PHARMACEUTICALS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| CN-1159288-C | Protein modifier, preparation method and use thereof | 中国科学院过程工程研究所 | 2004-07-28 | — | — | CN | disclosed |
| CN-1405150-A | Protein modifier, preparation method and use thereof | PROCESS INST CHINESE ACADEMY O (CN) | 2003-03-26 | — | — | CN | disclosed |
| CN-1048703-A | Novel propylene acid amides, its preparation method, contain the pharmaceutical preparation of this composition and the application in medicine thereof | RICHTER GEDEON VEGYESZET (HU) | 1991-01-23 | — | — | CN | disclosed |
| US-4328367-A | HERBICIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-05-04 | — | — | US | disclosed |
| US-4325954-A | ANTIDEPRESSANTS | LABORATOIRES JACQUES LOGEAIS (FR) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038109-A1 | Macromolecular platinum chelates | FOLR1, LIG3, ABCC1 | GAA 2797/4885CHRM1 3135/4885MGAM 4195/4885 |
| US-20230174497-A1 | RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION | RECQL, MRTO4, SNU13 | GAA 4319/4885CHRM1 4857/4885MGAM 4859/4885 |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | GAA 317/4885CHRM1 520/4885MGAM 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.